Stocksigma LogoStocksigma Logo

Hester Biosciences Posts Strong Q2 & H1 FY27 Operational Performance

Hester Biosciences reported strong Q2 FY27 standalone revenue growth of 28% YoY, with PAT surging 131% YoY

Hester Biosciences Posts Strong Q2 & H1 FY27 Operational Performance

Hester Biosciences Ltd 路 Transcript 路 07 Nov 2026, 8:31 pm

Hester Biosciences Posts Strong Q2 & H1 FY27 Operational Performance Hester Biosciences reported strong Q2 FY27 standalone revenue growth of 28% YoY, with PAT surging 131% YoY. Standalone gross margin reached 78% and EBITDA margin stood at 35%, driven by favorable product mix and operational discipline despite newly capitalized BSL-3 depreciation. Consolidated Q2 revenue rose 38% YoY, while PAT increased 44% YoY. Poultry Healthcare expanded 27% YoY in Q2 (37% in H1), aided by H9N2 vaccine traction and institutional sales. Capacity utilization stood near 65%, with net debt reduced to approximately INR80 crore.

Original exchange filing (PDF)

More announcements from Hester Biosciences Ltd

All Hester Biosciences Ltd announcements